ADHD

A panelist discusses how attention deficit/hyperactivity disorder (ADHD) as a common neurodevelopmental disorder characterized by inattention and hyperactive-impulsive behavior, affecting approximately 10.5% of children in the US aged 3 to 17 years with higher prevalence in adolescents and boys, highlighting its various symptoms, potential causes including genetic factors, and mentioning upcoming discussions about treatment options and transitioning care from pediatric to adult settings.

The FOCUS phase 3 trial of solriamfetol for the treatment of ADHD demonstrated statistically significant improvements in ADHD symptoms and disease severity.

Discover key insights from February’s Special Report on child and adolescent psychiatry, exploring overlooked diagnoses, new research, and the complex impact of social media on youth mental health.

Here are highlights from this week in Psychiatric Times, including a special report on psychiatric symptoms of celiac disease and the potential dangers of cannabis use in older patients.

A recent meta-analysis compares efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for adults with ADHD.

According to research, symptoms of ADHD are more often overlooked or diagnosed later in children with higher cognitive ability, physical activity, or social skills.

Here are highlights from this week in Psychiatric Times, including FDA news and a look back at Psychiatric Times through the years.

Check out these insights from clinicians at Real Psychiatry!

According to a new label update, the transfer of Qelbree into breastmilk is low.

Here are highlights from this week in Psychiatric Times, including FDA approvals and conference coverage.

What 5 factors should you look at when selecting ADHD treatment?

Let's define success for patients with ADHD...

When a patient has comorbidities like anxiety, substance use, and depression, how can you best select a treatment?

When prescribing ADHD medications, when is the best time to switch treatments?

Ancillary symptoms may be key in guiding treatment management for ADHD.

Comorbid bipolar disorder and ADHD: a big problem.

A poster at the ACNP Annual Meeting utilized a novel risk-informed case-control design to improve biomarker differentiation for ADHD.

ADHD doubles the rates of all-cause mortality. How can you best help patients?

Adultd ADHD: What are the best practices and how do we apply the science? An expert weighs in.

It’s time to address adult ADHD.

Recent research has highlighted important functional aspects of vitamin D. Learn more here.

Explore the most recent data on adult ADHD with the president of the American Professional Society for ADHD and Related Disorders.

The CDC just released new data that highlight issues around adult ADHD prevalence, diagnosis, and treatment.

A new study of adult emergency department admissions found that individuals taking high doses of amphetamine—like Adderall—have a 5-fold increased risk for developing psychosis or mania.

Guidelines from the World Health Organization's Mental Health Gap Action Program support nonspecialist health workers providing evidence-based treatments in underresourced regions.

The CDC suggests that disrupted access to ADHD medications may increase risk of overdose and injury.

Do physical health conditions in childhood affect ADHD symptoms at age 17 years? Researchers investigated these associations in a large cohort study.

Onyda XR is the first and only liquid nonstimulant ADHD medication approved in the US and the only approved nonstimulant ADHD medication with nighttime dosing.

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Here are highlights from the week in Psychiatric Times.